Literature DB >> 34265444

Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.

Omar T Ahmed1, Tolga Gidener1, Kristin C Mara2, Joseph J Larson2, Terry M Therneau2, Alina M Allen3.   

Abstract

BACKGROUND & AIMS: The natural history of lean nonalcoholic fatty liver disease (NAFLD) is not well-understood. Consequently, patient counseling and disease management are limited. We aimed to compare the natural history of lean, overweight, and obese NAFLD in a U.S. population with long-term follow-up.
METHODS: All adults diagnosed with NAFLD in Olmsted County, MN between 1996 and 2016 were identified, and all subsequent medical events were ascertained using a medical record linkage system. Subjects were divided on the basis of body mass index (BMI) at NAFLD diagnosis into 3 groups: normal, overweight, and obese. The probability to develop cirrhosis, decompensation, malignancies, cardiovascular events, or death among the 3 groups was estimated by using the Aalen-Johansen method, treating death as a competing risk. The impact of BMI categories on these outcomes was explored by using Cox proportional hazards regression analysis.
RESULTS: A total of 4834 NAFLD individuals were identified: 414 normal BMI, 1189 overweight, and 3231 obese. Normal BMI NAFLD individuals were characterized by a higher proportion of women (66% vs 47%) and lower prevalence of metabolic comorbidities than the other 2 groups. In reference to obese, those with normal BMI NAFLD had a nonsignificant trend toward lower risk of cirrhosis (hazard ratio [HR], 0.33, 95% confidence interval [CI], 0.1-1.05). There were no significant differences in the risk of decompensation (HR, 0.79; 95% CI, 0.11-5.79), cardiovascular events (HR, 1.05; 95% CI, 0.73-1.51), or malignancy (HR, 0.87; 95% CI, 0.51-1.48). Compared with obese, normal BMI NAFLD had higher risk of all-cause mortality (HR, 1.96; 95% CI, 1.52-2.51).
CONCLUSIONS: NAFLD with normal BMI is associated with a healthier metabolic profile and possibly a lower risk of liver disease progression but similar risk of cardiovascular disease and malignancy than obese NAFLD.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMI; Lean; Mortality; NAFLD; Non-obese

Mesh:

Year:  2021        PMID: 34265444      PMCID: PMC8755855          DOI: 10.1016/j.cgh.2021.07.016

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  25 in total

Review 1.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

2.  Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.

Authors:  Shahinul Alam; Utpal Das Gupta; Mahbubul Alam; Jahangir Kabir; Ziaur Rahman Chowdhury; A K M Khorshed Alam
Journal:  Indian J Gastroenterol       Date:  2014-07-15

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

Review 4.  Epidemiology and natural history of non-alcoholic fatty liver disease.

Authors:  Yousef Fazel; Aaron B Koenig; Mehmet Sayiner; Zachary D Goodman; Zobair M Younossi
Journal:  Metabolism       Date:  2016-01-29       Impact factor: 8.694

5.  The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.

Authors:  Alina M Allen; Stephen B Hicks; Kristin C Mara; Joseph J Larson; Terry M Therneau
Journal:  J Hepatol       Date:  2019-08-27       Impact factor: 25.083

6.  Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Authors:  Anna Ludovica Fracanzani; Salvatore Petta; Rosa Lombardi; Giuseppina Pisano; Maurizio Russello; Dario Consonni; Vito Di Marco; Calogero Cammà; Laura Mensi; Paola Dongiovanni; Luca Valenti; Antonio Craxì; Silvia Fargion
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-26       Impact factor: 11.382

Review 7.  Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies.

Authors:  Abel Romero-Corral; Victor M Montori; Virend K Somers; Josef Korinek; Randal J Thomas; Thomas G Allison; Farouk Mookadam; Francisco Lopez-Jimenez
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

8.  Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Jeremy Lok Wei; Grace Lai-Hung Wong; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Sally She-Ting Shu; Angel Mei-Ling Chim; Henry Lik-Yuen Chan; Vincent Wai-Sun Wong
Journal:  Hepatology       Date:  2016-07-25       Impact factor: 17.425

9.  The obesity paradox in acute coronary syndrome: a meta-analysis.

Authors:  Jacek Niedziela; Bartosz Hudzik; Natalia Niedziela; Mariusz Gąsior; Marek Gierlotka; Jarosław Wasilewski; Krzysztof Myrda; Andrzej Lekston; Lech Poloński; Piotr Rozentryt
Journal:  Eur J Epidemiol       Date:  2014-10-30       Impact factor: 8.082

Review 10.  The Obesity Paradox in Cancer: a Review.

Authors:  Hannah Lennon; Matthew Sperrin; Ellena Badrick; Andrew G Renehan
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

View more
  4 in total

1.  AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

Authors:  Michelle T Long; Mazen Noureddin; Joseph K Lim
Journal:  Gastroenterology       Date:  2022-07-14       Impact factor: 33.883

Review 2.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

3.  Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants.

Authors:  Kemin Li; Ji Li; Xiaoyun Cheng; Jing Wang; Jingnan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

Review 4.  NAFLD in normal weight individuals.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Diabetol Metab Syndr       Date:  2022-03-24       Impact factor: 5.395

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.